Theragen Etex

테라젠이텍스 · 066700

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$66.4M (₩91.6B)

Overview

Theragen Etex makes prescription and over-the-counter medicines and also provides genomic analysis services, sequencing DNA and decoding RNA variations to help understand genetic information.

Its pharmaceutical products are used in clinical and consumer health settings, while its genomic services are supplied to research and health-care customers. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business divisions, pharmaceuticals and genomic analysis, alongside new-drug research and development.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$196.8M

▲ +8.8% YoY

Operating profit · FY2025

US$7.4M

▼ −18.3% YoY

Net income · FY2025

US$8.5M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$160.7M(₩221.7B)	US$180.9M(₩249.6B)	US$196.8M(₩271.6B)
Operating profit	US$8.4M(₩11.6B)	US$9.1M(₩12.5B)	US$7.4M(₩10.2B)
Net income	US$20.6M(₩28.4B)	−US$28.5M(−₩39.3B)	US$8.5M(₩11.7B)

Revenue

FY2023US$160.7M
FY2024US$180.9M
FY2025US$196.8M

Operating profit

FY2023US$8.4M
FY2024US$9.1M
FY2025US$7.4M

Net income

FY2023US$20.6M
FY2024−US$28.5M
FY2025US$8.5M

Key ratios (FY2025)

ROE

7.4%

Debt/Eq

61.9%

Op. margin

3.8%

Net margin

4.3%

Rev. YoY

▲ +8.8%

Why it matters

Its genomic analysis operations extend beyond Korea through overseas entities established specifically to expand DNA and RNA sequencing services into China, including Beijing-based and Hong Kong-registered subsidiaries named in its filing.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?